NZ553239A - Process for concentration of antibodies and proteins - Google Patents

Process for concentration of antibodies and proteins

Info

Publication number
NZ553239A
NZ553239A NZ553239A NZ55323905A NZ553239A NZ 553239 A NZ553239 A NZ 553239A NZ 553239 A NZ553239 A NZ 553239A NZ 55323905 A NZ55323905 A NZ 55323905A NZ 553239 A NZ553239 A NZ 553239A
Authority
NZ
New Zealand
Prior art keywords
protein
ultrafiltering
protein preparation
antibody
diafiltering
Prior art date
Application number
NZ553239A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ553239(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of NZ553239A publication Critical patent/NZ553239A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
NZ553239A 2004-09-09 2005-09-08 Process for concentration of antibodies and proteins NZ553239A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
NZ553239A true NZ553239A (en) 2009-11-27

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ553239A NZ553239A (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and proteins

Country Status (32)

Country Link
US (6) US20060051347A1 (enExample)
EP (5) EP1786830B1 (enExample)
JP (2) JP5210633B2 (enExample)
KR (2) KR101528970B1 (enExample)
CN (3) CN102911268A (enExample)
AR (1) AR050641A1 (enExample)
AU (1) AU2005285243C1 (enExample)
BR (1) BRPI0515649B8 (enExample)
CA (1) CA2577317C (enExample)
DK (5) DK2292636T3 (enExample)
EC (1) ECSP077282A (enExample)
ES (5) ES2975166T3 (enExample)
FI (4) FI2292636T3 (enExample)
GT (1) GT200500254A (enExample)
HU (4) HUE061899T2 (enExample)
IL (2) IL181372A (enExample)
LT (4) LT4104859T (enExample)
MA (1) MA28991B1 (enExample)
MX (2) MX342788B (enExample)
MY (2) MY150549A (enExample)
NO (1) NO333660B1 (enExample)
NZ (1) NZ553239A (enExample)
PE (1) PE20060816A1 (enExample)
PL (5) PL4104859T3 (enExample)
PT (5) PT4104859T (enExample)
RU (1) RU2390524C2 (enExample)
SG (1) SG177161A1 (enExample)
SI (5) SI4104859T1 (enExample)
TN (1) TNSN07069A1 (enExample)
TW (1) TWI372630B (enExample)
WO (1) WO2006031560A2 (enExample)
ZA (1) ZA200701626B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
EP2072040B1 (en) 2004-05-12 2013-05-01 Baxter International Inc. Therapeutic use of nucleic acid micropheres
US7884085B2 (en) 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
WO2007120449A1 (en) * 2006-03-31 2007-10-25 Genencor International, Inc. Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
NZ582045A (en) * 2006-04-04 2011-07-29 Zymenex As A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
RU2504549C2 (ru) 2007-07-17 2014-01-20 Ф.Хоффманн-Ля Рош Аг Фильтрация в переменном тангенциальном потоке
CA2706403A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
RU2473360C2 (ru) * 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2406029T3 (es) * 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
DK2280999T3 (da) * 2008-05-15 2017-11-13 Biosys Health Inc Fremgangsmåde til fremstilling af mælkefraktioner, som er rige på sekretoriske immunglobuliner
WO2010066634A1 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
EP2411125B1 (en) * 2009-03-24 2019-05-08 Wyeth LLC Membrane evaporation for generating highly concentrated protein therapeutics
MY157239A (en) * 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011039012A1 (en) 2009-09-29 2011-04-07 F. Hoffmann-La Roche Ag Pre-filtration adjustment of buffer solutes
CN104610447A (zh) 2009-10-01 2015-05-13 弗·哈夫曼-拉罗切有限公司 多步骤的最终过滤
TR201903403T4 (tr) 2010-02-04 2019-04-22 Csl Behring Ag İmmünoglobulin preparatı.
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
ES2625511T3 (es) 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
AU2012303372A1 (en) * 2011-09-01 2014-02-20 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2938357A1 (en) * 2012-12-28 2015-11-04 Novo Nordisk A/S High temperature dead end antibody filtration
CN104903442A (zh) 2013-01-09 2015-09-09 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CN112588116A (zh) 2014-05-13 2021-04-02 美国安进公司 用于过滤器和过滤过程的过程控制系统和方法
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
EP2986361B1 (en) 2014-06-25 2019-06-12 EMD Millipore Corporation Compact spiral-wound membrane filter elements
SG11201508664VA (en) 2014-08-29 2016-03-30 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
CN108325391B (zh) 2014-08-29 2021-05-18 Emd 密理博公司 过滤液体进料的方法
EP3209332B1 (en) 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US12144861B2 (en) 2014-12-03 2024-11-19 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
ES2925059T3 (es) 2016-06-09 2022-10-13 Emd Millipore Corp Elementos de filtro de trayectoria radial, sistemas y métodos de uso de los mismos
BR112019003013A2 (pt) * 2016-08-16 2019-05-14 Genzyme Corporation métodos de processamento de um fluido incluindo uma proteína terapêutica recombinante e uso do mesmo
KR102457855B1 (ko) * 2016-08-17 2022-10-25 베링거 인겔하임 인터내셔날 게엠베하 생체 분자를 함유하는 고농축 액상 제형의 제조 방법
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
MA52204A (fr) * 2018-04-12 2021-02-17 Amgen Inc Procédés de préparation de compositions protéiques stables
TWI846694B (zh) 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
WO2020033788A1 (en) * 2018-08-10 2020-02-13 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
KR20250174710A (ko) * 2018-08-14 2025-12-12 브리스톨-마이어스 스큅 컴퍼니 개선된 단백질 회수
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
AU2020223376A1 (en) * 2019-02-15 2021-07-22 Just - Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
PH12021553189A1 (en) * 2019-07-31 2022-11-07 Catalent Uk Swindon Zydis Ltd Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
CN116406369A (zh) * 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
KR20230108301A (ko) 2020-11-23 2023-07-18 아벡, 아이엔씨. 여과 시스템, 구성요소 및 방법
EP4304764A1 (en) * 2021-03-08 2024-01-17 Boehringer Ingelheim International GmbH Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
CN118871579A (zh) 2022-02-25 2024-10-29 美国安进公司 制备高浓度液体原料药的方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
AU2023306365A1 (en) * 2022-07-12 2025-02-13 Beone Medicines I Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (enExample) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (enExample) 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
JP2001516599A (ja) * 1997-09-22 2001-10-02 セプラジェン コーポレーション ホエータンパク質の逐次分離およびその配合物
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
UY26236A1 (es) 1999-07-07 2000-10-31 New Zeland Co Operative Dairy Metodos para obtener aislados de proteina y concentrados de calostro
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
EP2311492B1 (en) * 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
JP2005521640A (ja) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
AU2003287299A1 (en) * 2002-11-01 2004-06-07 Bayer Healthcare Llc Process for concentration of macromolecules
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
JP2006515227A (ja) * 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
EP2335725B1 (en) 2003-04-04 2016-10-12 Genentech, Inc. High concentration antibody and protein formulations
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
WO2005082109A2 (en) 2004-02-26 2005-09-09 Massachusetts Institute Of Technology Solution additives for the attenuation of protein aggregation
WO2006018956A1 (ja) 2004-08-19 2006-02-23 Electronic Navigation Research Institute, An Independent Administrative Institution 誘電体レンズを用いた装置
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Also Published As

Publication number Publication date
ES2983099T3 (es) 2024-10-22
ECSP077282A (es) 2007-03-29
EP3805248B1 (en) 2023-01-18
JP5426641B2 (ja) 2014-02-26
CN101056885B (zh) 2015-08-26
CN104961797B (zh) 2020-12-25
JP2008512473A (ja) 2008-04-24
US20090214522A1 (en) 2009-08-27
EP4104859A1 (en) 2022-12-21
ES2528541T3 (es) 2015-02-10
TWI372630B (en) 2012-09-21
NO20071432L (no) 2007-03-16
HK1215869A1 (zh) 2016-09-23
FI3805248T3 (fi) 2023-04-21
DK1786830T3 (en) 2015-01-19
DK2292636T3 (da) 2024-01-15
HUE065025T2 (hu) 2024-04-28
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
EP2292636B1 (en) 2023-10-18
ES2975166T3 (es) 2024-07-03
AU2005285243C1 (en) 2012-10-25
HUE061899T2 (hu) 2023-08-28
TW200612989A (en) 2006-05-01
TNSN07069A1 (en) 2008-06-02
SI2292636T1 (sl) 2024-02-29
MA28991B1 (fr) 2007-11-01
BRPI0515649B1 (pt) 2021-10-13
DK3805248T3 (da) 2023-04-03
PL2292636T3 (pl) 2024-03-11
IL181372A0 (en) 2007-07-04
ES2968070T3 (es) 2024-05-07
EP1786830A2 (en) 2007-05-23
LT4104859T (lt) 2024-07-10
ES2942574T3 (es) 2023-06-02
CN102911268A (zh) 2013-02-06
HUE067296T2 (hu) 2024-10-28
MY150549A (en) 2014-01-30
KR20070109975A (ko) 2007-11-15
PT4104859T (pt) 2024-07-02
PT3805248T (pt) 2023-04-05
FI4104859T3 (fi) 2024-07-16
EP3805248A3 (en) 2021-07-14
EP2292636A3 (en) 2013-05-01
SI3805248T1 (sl) 2023-05-31
EP1786830B1 (en) 2014-11-12
PT1786830E (pt) 2015-02-05
US20210095050A1 (en) 2021-04-01
EP2292636A2 (en) 2011-03-09
RU2390524C2 (ru) 2010-05-27
FI2292636T3 (fi) 2024-01-12
LT4108259T (lt) 2024-04-10
PT4108259T (pt) 2024-03-07
MX2007002812A (es) 2007-05-16
BRPI0515649A (pt) 2008-07-29
PT2292636T (pt) 2024-01-09
KR20120135530A (ko) 2012-12-14
MY162525A (en) 2017-06-15
JP5210633B2 (ja) 2013-06-12
PL4104859T3 (pl) 2024-08-26
SI4104859T1 (sl) 2024-08-30
EP2292636B9 (en) 2024-01-03
DK3805248T5 (da) 2023-04-24
US11767370B2 (en) 2023-09-26
ZA200701626B (en) 2008-10-29
CA2577317A1 (en) 2006-03-23
PL3805248T3 (pl) 2023-05-22
SI4108259T1 (sl) 2024-04-30
HK1101249A1 (en) 2007-10-12
EP4104859B1 (en) 2024-04-17
WO2006031560A3 (en) 2006-08-24
BRPI0515649B8 (pt) 2021-11-03
AU2005285243A1 (en) 2006-03-23
KR101528970B1 (ko) 2015-06-15
US20230074486A1 (en) 2023-03-09
EP4108259B1 (en) 2024-01-03
IL181372A (en) 2012-01-31
JP2012097086A (ja) 2012-05-24
US20140370003A1 (en) 2014-12-18
HUE067662T2 (hu) 2024-11-28
SG177161A1 (en) 2012-01-30
AR050641A1 (es) 2006-11-08
US12371510B2 (en) 2025-07-29
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
SI1786830T1 (sl) 2015-03-31
CN101056885A (zh) 2007-10-17
NO333660B1 (no) 2013-08-05
DK4104859T3 (da) 2024-07-08
US20070237762A1 (en) 2007-10-11
PL1786830T3 (pl) 2015-05-29
PE20060816A1 (es) 2006-09-02
DK4108259T3 (da) 2024-03-11
LT3805248T (lt) 2023-04-25
WO2006031560A2 (en) 2006-03-23
IL216851A0 (en) 2012-01-31
PL4108259T3 (pl) 2024-05-13
US10370456B2 (en) 2019-08-06
MX342788B (es) 2016-10-12
KR101528970B9 (ko) 2022-12-09
US20060051347A1 (en) 2006-03-09
CN104961797A (zh) 2015-10-07
AU2005285243B2 (en) 2012-03-08
EP4108259A1 (en) 2022-12-28
CA2577317C (en) 2016-04-26
FI4108259T3 (fi) 2024-09-10

Similar Documents

Publication Publication Date Title
US11767370B2 (en) Process for concentration of antibodies and therapeutic products thereof
HK40047421A (en) Process for concentration of antibodies and therapeutic products thereof
HK40047421B (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186A (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042A (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042B (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186B (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343A (en) Process for concentration of antibodies and therapeutic products thereof
HK1101249B (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343B (en) Process for concentration of antibodies and therapeutic products thereof
HK1215869B (zh) 濃縮抗體的方法及其治療性產品
HK1178178A (en) Process for concentration of antibodies and therapeutic products thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 161198, GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CALIFORNIA 94080-4990, US; 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2016 BY THOMSON REUTERS

Effective date: 20150827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2017 BY THOMSON REUTERS

Effective date: 20160816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2018 BY THOMSON REUTERS

Effective date: 20170819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2020 BY THOMSON REUTERS

Effective date: 20190817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2021 BY THOMSON REUTERS

Effective date: 20200820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2022 BY THOMSON REUTERS

Effective date: 20210803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2023 BY THOMSON REUTERS

Effective date: 20220801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2025 BY ANAQUA SERVICES

Effective date: 20240820

EXPY Patent expired